Retatrutide is designed as a triple-receptor agonist, while tirzepatide targets two incretin receptors. The original overview of this page asks readers to keep those designs distinct, to use matched receptor and concentration controls, and to document identity, content, and aggregation separately for each analogue.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not a ranking, not claims about a Velnacor lot, and not instructions for use in people or animals.
Triple GIP/GLP-1/glucagon versus dual GIP/GLP-1 design
Coskun and colleagues described LY3298176, later identified as tirzepatide, as a fatty-acid-modified dual GIP and GLP-1 receptor agonist (Coskun et al., 2018; Jastreboff et al., 2022). The same group described LY3437943, later identified as retatrutide, as a triple agonist at the glucagon, GIP, and GLP-1 receptors, with in-vitro activity they characterized as balanced at GCGR and GLP-1R and relatively greater at GIPR (Coskun et al., 2022; Jastreboff et al., 2023). The extra glucagon-receptor engagement is a documentation fact, not a reason to treat the two peptides as interchangeable reagents. Semaglutide, a selective GLP-1 analogue, is a third row; see Semaglutide: GLP-1-Analogue Identity, Sequence Modifications, and Laboratory Documentation. Identity notes for each analogue are at What Is Retatrutide? and Tirzepatide: Dual GIP/GLP-1 Agonist Identity and Laboratory Documentation.
| Name | What the cited literature identifies | What not to assume |
|---|---|---|
| Tirzepatide | A dual GIP/GLP-1 receptor agonist (LY3298176) (Coskun et al., 2018; Jastreboff et al., 2022). | That a dual-agonist result documents a triple agonist, or a selective GLP-1 analogue. |
| Retatrutide | A triple glucagon/GIP/GLP-1 receptor agonist (LY3437943) (Coskun et al., 2022; Jastreboff et al., 2023). | That phase 2 body-weight findings in one paper can be filed under tirzepatide. |
Published findings, and why this is not a ranking
Jastreboff and colleagues reported substantial body-weight reduction with tirzepatide versus placebo at week 72 in SURMOUNT-1, a phase 3 trial in adults with obesity or with overweight plus a weight-related complication, excluding diabetes (Jastreboff et al., 2022). In a separate phase 2 trial, the same first author and colleagues reported larger least-squares mean percentage reductions in body weight with retatrutide than with placebo at 24 and 48 weeks (Jastreboff et al., 2023). Those are findings in different designs, durations, and study populations. They are not a pooled efficacy table.
Frías and colleagues compared tirzepatide with semaglutide, not with retatrutide, in type 2 diabetes (SURPASS-2) and reported that tirzepatide was noninferior and superior to semaglutide for the mean change in glycated hemoglobin at 40 weeks (Frías et al., 2021). That paper does not fill the retatrutide–tirzepatide comparison on this page.
Citation flag. A single peer-reviewed, head-to-head randomized trial that compared retatrutide with tirzepatide in one experimental design was not verified for this draft. The comparison is a documentation framework built from identity papers and from findings reported for each analogue in its own literature.
Matched controls and separate lot files
When both analogues appear in the same file, receptor assays, concentrations, and reports should be specified per material. Combination SKUs, if offered, are additional rows. How to Read a Peptide COA, lot traceability, and How to Evaluate a Peptide Supplier: B2B Checklist apply independently to each line item.
Catalog records exist for retatrutide, tirzepatide, and a combination SKU. There is not a standalone public landing page for every name; use the product directory and the COA Library, then confirm each SKU in the inquiry. For packing at supply scale, see wholesale peptides.
Selected published literature
- Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. PubMed 30473097.
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O’Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PubMed 35985340.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PubMed 35658024. Cited as published clinical-research observations, not as a use instruction.
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PubMed 37366315. Cited as published clinical-research observations, not as a use instruction.
- Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PubMed 34170647. Cited to show a published comparison of tirzepatide with semaglutide, not with retatrutide, and not as a use instruction.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.